X0306 4 2022-10-18 0 0001831828 Vera Therapeutics, Inc. VERA 0001857670 Curley Joanne C/O VERA THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 120 BRISBANE CA 94005 0 1 0 0 Chief Development Officer Class A Common Stock 2022-10-18 4 M 0 1078 6.3728 A 28887 D Class A Common Stock 2022-10-18 4 S 0 1078 19.4304 D 27809 D Class A Common Stock 2022-10-18 4 M 0 2212 2.8968 A 30021 D Class A Common Stock 2022-10-18 4 S 0 2212 19.3865 D 27809 D Class A Common Stock 2022-10-18 4 M 0 5298 11.00 A 33107 D Class A Common Stock 2022-10-18 4 S 0 5298 19.4159 D 27809 D Class A Common Stock 2022-10-18 4 M 0 2 11.00 A 27811 D Class A Common Stock 2022-10-18 4 S 0 2 20.30 D 27809 D Stock Option (right to buy) 6.3728 2022-10-18 4 M 0 1078 0.00 D 2030-03-31 Class A Common Stock 1078 10795 D Stock Option (right to buy) 2.8968 2022-10-18 4 M 0 2212 0.00 D 2030-12-15 Class A Common Stock 2212 40224 D Stock Options (right to buy) 11.00 2022-10-18 4 M 0 5300 0.00 D 2031-05-12 Class A Common Stock 5300 84017 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.07 to $19.89, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.04 to $19.89, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.05 to $19.93, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. 1/4 of the shares subject to the option vested on March 12, 2021, and 1/48 of the shares vest monthly thereafter. 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. 1/4 of the shares subject to the option vested on May 13, 2022, and 1/48 of the shares vest monthly thereafter. /s/ Joseph R. Young, Attorney-in-Fact 2022-10-20